logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11242406 B1

PDFFull Text
Date of Patent:
Feb. 08, 2022

Filed:

Jul. 07, 2017

Methods for the treatment of a cancer or fibrotic disorder associated with mena or mena(inv) by administering a map kinase inhibitor

Applicant:

Metastat, Inc., Boston, MA (US);

Inventors:

Douglas A. Hamilton, Boston, MA (US);

Anna L. Blois, Boston, MA (US);

Assignee:

METASTAT, INC., Boston, MA (US);

Attorneys:

Christopher M. Cabral

Much Shelist PC

Primary Examiner:

Robert S Landsman

Int. Cl.
CPC ...
C07K 16/40 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61K 9/00 (2006.01); C07K 7/00 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 31/337 (2006.01); A61P 9/00 (2006.01); A61K 31/5377 (2006.01); A61K 31/7105 (2006.01); G01N 33/50 (2006.01); A61K 31/167 (2006.01); A61K 31/166 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/337 (2013.01); A61K 31/5377 (2013.01); A61K 31/7105 (2013.01); A61K 39/395 (2013.01); A61P 9/00 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 16/2896 (2013.01); G01N 33/5011 (2013.01); A61K 31/166 (2013.01); A61K 31/167 (2013.01); C07K 7/00 (2013.01); C07K 2317/76 (2013.01);
Abstract

Phosphorylation and dephosphorylation of MENA and MENA isoforms regulates the metastatic activity of cancer cells. Administration of a MENA kinase inhibitor results in significant reduction in the development of cancer metastasis in established and developing tumors. Administration of a MENA kinase inhibitor in conjunction with a tyrosine kinase inhibitor enhances efficacy of tyrosine kinase inhibitor therapy. Administration of a MENA kinase inhibitor in conjunction with anti-microtubule agent results in significant reduction in chemotherapy-induced tumor cell dissemination and enhances efficacy of anti-microtubule therapy.

Find Patent Forward Citations

Loading…